Codex DNA, Inc. today announced the release of seven new synthetic SARS-CoV-2 genomes for use in the development of vaccines, therapeutics, and diagnostics to help in the COVID-19 pandemic response.
You Might Also Like
Quanterix Receives FDA Emergency Use Authorization For SARS-CoV-2 N Protein Antigen Test
NanoString’s CosMx Spatial Molecular Imager Recognized by The Scientist Magazine as a Top 10 Innovation of 2022
